Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 7,597,895 entitled "Signal peptides, nucleic acid molecules and methods for treatment of caries" by the U.S. Patent and Trademark Office. This is the third patent to issue protecting Kane Biotech's CSP (Competence Stimulating Peptide) technology.
This patent claims a composition such as toothpaste, mouthwash, a food additive or chewing gum containing Kane's CSP analogue peptide called E2 and an additional analogue and/or a monoclonal antibody, antibiotic or antioxidant. The two previously issued US patents (6,923,962 & 7,556,807) claim isolated as well as synthetic CSP, and a method of preventing and treating dental plaque associated conditions such as dental cavities and periodontal disease using analogues of CSP in oral care formulations. Dr. Dennis Cvitkovitch (Dental Research Institute, University of Toronto), discoverer of CSP in Streptococcus mutans, demonstrated the ability of CSP analogue peptides to inhibit dental cavities-associated streptococcal biofilm (plaque) formation.
"We have demonstrated a significant synergistic inhibitory effect of combining E2 with selected antimicrobials on dental cavities-associated Streptococci, including S. mutans. This shows that an oral care product containing E2 analogue with either an antibody or antibiotic will be more effective than using the analogue alone in preventing dental cavities", stated Dr. Sri Madhyastha, Vice President, Research and Chief Scientific Officer of Kane Biotech.
Squid-inspired technology could replace needles for medications and vaccines